Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19.

  • 2024-07-13
  • European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 281(11)
    • Mohamed H Abdelazim
    • Faisal Alsenani
    • Mohammed Alnuhait
    • Abdullah S Alshammari
    • Abdullah H Altemani
    • Eyad A Althagafi
    • Dania S Waggas
    • Ahmed H Abdelazim
    • Adnan Alharbi

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 285
Population
285 participants with persistent olfactory dysfunction post COVID-19 infection
Methods
prospective randomized clinical trial, oral forskolin capsules vs placebo capsules
  • Large Human Trial

Purpose

Olfactory dysfunction is increasingly common among COVID-19 patients, impacting their well-being. Reports have demonstrated decreased levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate among patients with chronic olfactory dysfunction. A prospective randomized clinical trial was developed to demonstrate the efficacy of an oral forskolin regimen treatment, an adenylyl cyclase activator that raises intracellular levels of cyclic adenosine monophosphate, for the treatment of olfactory dysfunction following COVID-19, compared to placebo regimen.

Methods

The study enrolled 285 participants with persistent olfactory dysfunction post COVID-19 infection, randomly assigning them to receive either placebo capsules (n = 120) or oral forskolin capsules (n = 165). Follow-up was conducted to track progress, with 18 participants from the placebo group and 12 from the forskolin group lost during this period. Olfactory function was assessed using the "Sniffin' Sticks" test, measuring threshold, discrimination and identification scores before and after treatment.

Results

Subjects administered forskolin capsules demonstrated a significant enhancement in their composite TDI (threshold, discrimination and identification) score, suggesting a notable amelioration in olfactory functionality. Moreover, the discrimination and identification scores notably improved within the forskolin group. Conversely, no significant alterations were observed in the threshold scores.

Conclusion

This study suggests that forskolin can contribute potentially to improve chronic olfactory dysfunction post COVID-19.

Trial registration

DFM-IRB00012367-23-10-001.

Research Insights

Back to top